BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 21740228)

  • 1. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria.
    Bush K; Fisher JF
    Annu Rev Microbiol; 2011; 65():455-78. PubMed ID: 21740228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae.
    Bush K
    Curr Opin Microbiol; 2010 Oct; 13(5):558-64. PubMed ID: 20920882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology of infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant strains.
    Rossolini GM; Mantengoli E; Docquier JD; Musmanno RA; Coratza G
    New Microbiol; 2007 Jul; 30(3):332-9. PubMed ID: 17802921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
    Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
    Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The emergence and implications of metallo-beta-lactamases in Gram-negative bacteria.
    Walsh TR
    Clin Microbiol Infect; 2005 Nov; 11 Suppl 6():2-9. PubMed ID: 16209700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases.
    Shah AA; Hasan F; Ahmed S; Hameed A
    Res Microbiol; 2004; 155(6):409-21. PubMed ID: 15249058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
    Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
    Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinically important beta-lactamases of gram-negative bacteria: extended-spectrum beta-lactamases (ESBL)].
    Hrabák J
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):103-11. PubMed ID: 17900058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Delhi metallo-β-lactamase (NDM-1): an update.
    Shakil S; Azhar EI; Tabrez S; Kamal MA; Jabir NR; Abuzenadah AM; Damanhouri GA; Alam Q
    J Chemother; 2011 Oct; 23(5):263-5. PubMed ID: 22005056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy.
    Bush K
    Clin Infect Dis; 2001 Apr; 32(7):1085-9. PubMed ID: 11264037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IRT and CMT beta-lactamases and inhibitor resistance.
    Cantón R; Morosini MI; de la Maza OM; de la Pedrosa EG
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():53-62. PubMed ID: 18154528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.
    Bradford PA
    Clin Microbiol Rev; 2001 Oct; 14(4):933-51, table of contents. PubMed ID: 11585791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended spectrum beta-lactamases among Gram-negative bacteria of nosocomial origin from an intensive care unit of a tertiary health facility in Tanzania.
    Ndugulile F; Jureen R; Harthug S; Urassa W; Langeland N
    BMC Infect Dis; 2005 Oct; 5():86. PubMed ID: 16225701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens.
    Pfeifer Y; Cullik A; Witte W
    Int J Med Microbiol; 2010 Aug; 300(6):371-9. PubMed ID: 20537585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survey for beta-lactamase among bacterial isolates from Guangzhou, China hospitals between 2005-2006.
    Liao W; Jiang J; Xu Y; Yi J; Chen T; Su X; Pan S; Wei X; Li Y
    J Antibiot (Tokyo); 2010 May; 63(5):225-9. PubMed ID: 20339396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferation and significance of clinically relevant β-lactamases.
    Bush K
    Ann N Y Acad Sci; 2013 Jan; 1277():84-90. PubMed ID: 23346859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gram-negative bacteriae with resistance to carbapenems].
    Nordmann P
    Med Sci (Paris); 2010 Nov; 26(11):950-9. PubMed ID: 21106177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug resistance in Gram-negative bacteria that produce extended-spectrum beta-lactamases (ESBLs).
    Giamarellou H
    Clin Microbiol Infect; 2005 Jul; 11 Suppl 4():1-16. PubMed ID: 15953019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug-resistant Gram-negative bacteria: a product of globalization.
    Hawkey PM
    J Hosp Infect; 2015 Apr; 89(4):241-7. PubMed ID: 25737092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.